
FTRE
Fortrea Holdings Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
6.850
Open
6.850
VWAP
--
Vol
1.58M
Mkt Cap
575.58M
Low
6.235
Amount
--
EV/EBITDA(TTM)
--
Total Shares
89.37M
EV
1.73B
EV/OCF(TTM)
10.56
P/S(TTM)
0.23
Fortrea Holdings Inc. is a global contract research organization (CRO), which provides clinical development solutions to the life sciences industry. The Company is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The Company offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. It provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The Company manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The Company has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
631.46M
-4.67%
0.075
-350.87%
611.32M
-9.42%
0.149
-35.35%
613.87M
-11.93%
0.210
+16.61%
Estimates Revision
The market is revising Upward the revenue expectations for Fortrea Holdings Inc. (FTRE) for FY2025, with the revenue forecasts being adjusted by 1% over the past three months. During the same period, the stock price has changed by 0.47%.
Revenue Estimates for FY2025
Revise Upward

+1%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward

+6.51%
In Past 3 Month
Stock Price
Go Up

+0.47%
In Past 3 Month
10 Analyst Rating

-7.86% Downside
Wall Street analysts forecast FTRE stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for FTRE is 5.86 USD with a low forecast of 4.75 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
8 Hold
2 Sell
Hold

-7.86% Downside
Current: 6.360

Low
4.75
Averages
5.86
High
8.00

-7.86% Downside
Current: 6.360

Low
4.75
Averages
5.86
High
8.00
Mizuho
Neutral
downgrade
$8 -> $7
2025-07-11
Reason
Mizuho
Price Target
$8 -> $7
2025-07-11
downgrade
Neutral
Reason
Mizuho lowered the firm's price target on Fortrea to $7 from $8 and keeps a Neutral rating on the shares as part of a Q2 earnings preview. The firm believes earnings visibility is solid for the hospital group while cost trends remain challenging for managed care companies. Mizuho says its survey of 215 physicians is positive for hospitals, neutral for clinical labs, and neutral-to-negative for managed care.
Citi
Neutral
maintain
$6
2025-05-22
Reason
Citi
Price Target
$6
2025-05-22
maintain
Neutral
Reason
Mizuho
Neutral
downgrade
$10 -> $8
2025-05-14
Reason
Mizuho
Price Target
$10 -> $8
2025-05-14
downgrade
Neutral
Reason
Mizuho lowered the firm's price target on Fortrea to $8 from $10 and keeps a Neutral rating on the shares. The company reported a good Q1 earnings beat, but reported weaker than expected bookings trends driven by delays in awards for biotech clients and soft demand in clinical pharmacology, the analyst tells investors in a research note. The firm expects the funding backdrop and volatile macroeconomic environment coupled with the loss of its CEO to continue to put pressure on Fortrea.
TD Cowen
Charles Rhyee
Hold
downgrade
$7 -> $5
2025-05-14
Reason
TD Cowen
Charles Rhyee
Price Target
$7 -> $5
2025-05-14
downgrade
Hold
Reason
TD Cowen analyst Charles Rhyee lowered the firm's price target on Fortrea to $5 from $7 and keeps a Hold rating on the shares. The firm updated estimates to reflect continued soft biotech and large pharma.
Barclays
Luke Sergott
Underweight
downgrade
$6 -> $5
2025-05-13
Reason
Barclays
Luke Sergott
Price Target
$6 -> $5
2025-05-13
downgrade
Underweight
Reason
Barclays analyst Luke Sergott lowered the firm's price target on Fortrea to $5 from $6 and keeps an Underweight rating on the shares. The company's CEO is stepping down and it reported a bookings miss on big sales beat, the analyst tells investors in a research note. The firm expects the shares to respond positively outside of commentary that things are getting materially worse.
Barclays
Luke Sergott
Hold
to
Sell
Downgrades
$12 → $6
2025-04-10
Reason
Barclays
Luke Sergott
Price Target
$12 → $6
2025-04-10
Downgrades
Hold
to
Sell
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Fortrea Holdings Inc (FTRE.O) is 13.19, compared to its 5-year average forward P/E of 28.64. For a more detailed relative valuation and DCF analysis to assess Fortrea Holdings Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair
5Y Average PE
28.64
Current PE
13.19
Overvalued PE
45.27
Undervalued PE
12.01
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair
5Y Average EV/EBITDA
13.19
Current EV/EBITDA
9.79
Overvalued EV/EBITDA
17.08
Undervalued EV/EBITDA
9.31
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued
5Y Average PS
0.73
Current PS
0.25
Overvalued PS
1.03
Undervalued PS
0.43
Financials
Annual
Quarterly
FY2025Q1
YoY :
-1.63%
651.30M
Total Revenue
FY2025Q1
YoY :
-27.27%
-24.80M
Operating Profit
FY2025Q1
YoY :
+605.39%
-562.90M
Net Income after Tax
FY2025Q1
YoY :
+453.10%
-6.25
EPS - Diluted
FY2025Q1
YoY :
+264.18%
-127.10M
Free Cash Flow
FY2025Q1
YoY :
+14.63%
14.89
Gross Profit Margin - %
FY2025Q1
YoY :
+43.24%
5.40
FCF Margin - %
FY2025Q1
YoY :
+617.26%
-86.43
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
35.2K
USD
3
3-6
Months
49.2K
USD
7
6-9
Months
237.4K
USD
5
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
2.5M
Volume
1
3-6
Months
2.0M
Volume
1
6-9
Months
1.9M
Volume
5
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
2
1.2M
Volume
Months
6-9
3
2.0M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
8.0K
USD
1
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
35.2K
USD
3
3-6
Months
49.2K
USD
7
6-9
Months
237.4K
USD
5
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
FTRE News & Events
Events Timeline
2025-06-24 (ET)
2025-06-24
07:06:13
Fortrea announces strategic collaboration with Emery Pharma

2025-06-12 (ET)
2025-06-12
08:42:18
Fortrea adopts limited-duration stockholder rights plan

2025-06-11 (ET)
2025-06-11
16:13:22
Fortrea names Anshul Thakral as CEO

Sign Up For More Events
Sign Up For More Events
News
7.0
07-29PRnewswireINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Fortrea Holdings
7.0
07-29GlobenewswireDEADLINE ALERT for FTRE, VSTS: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
7.0
07-28GlobenewswireFORTREA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors in Fortrea Holdings (FTRE) of The August 1st Deadline and Urges Investors to Contact The Firm
Sign Up For More News
People Also Watch

TROX
Tronox Holdings PLC
5.520
USD
-3.83%

VET
Vermilion Energy Inc.
8.590
USD
0.00%

CLMT
Calumet Inc
16.430
USD
-2.26%

PHR
Phreesia Inc
27.120
USD
-0.04%

LTC
LTC Properties Inc
34.690
USD
+0.96%

HE
Hawaiian Electric Industries Inc
10.740
USD
+0.47%

CSTM
Constellium SE
14.680
USD
+5.38%

CLDX
Celldex Therapeutics Inc
21.950
USD
-0.27%

TVTX
Travere Therapeutics Inc
15.530
USD
+0.84%

DMLP
Dorchester Minerals LP
27.960
USD
+0.18%
FAQ

What is Fortrea Holdings Inc (FTRE) stock price today?
The current price of FTRE is 6.36 USD — it has decreased -7.42 % in the last trading day.

What is Fortrea Holdings Inc (FTRE)'s business?

What is the price predicton of FTRE Stock?

What is Fortrea Holdings Inc (FTRE)'s revenue for the last quarter?

What is Fortrea Holdings Inc (FTRE)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Fortrea Holdings Inc (FTRE)'s fundamentals?

How many employees does Fortrea Holdings Inc (FTRE). have?
